Your browser doesn't support javascript.
loading
Is endoscopic radiofrequency ablation plus stent placement superior to stent placement alone for the treatment of malignant biliary obstruction? A systematic review and meta-analysis.
Liu, Chenming; Dong, Jiaming; Liu, Yuxing; Zhang, Siyuan; Chen, Ruanchang; Tang, Haijun.
Afiliación
  • Liu C; Department of Hepatopancreatobiliary Surgery, Shaoxing People's Hospital, Shaoxing, PR China.
  • Dong J; Zhejiang University School of Medicine, Hangzhou, PR China.
  • Liu Y; Department of Hepatopancreatobiliary Surgery, Shaoxing People's Hospital, Shaoxing, PR China.
  • Zhang S; School of Medicine, ShaoXing University, Shaoxing, PR China.
  • Chen R; Department of Colorectal and Anal Surgery, Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, PR China.
  • Tang H; Zhejiang University School of Medicine, Hangzhou, PR China.
J Int Med Res ; 51(12): 3000605231220825, 2023 Dec.
Article en En | MEDLINE | ID: mdl-38156408
ABSTRACT

OBJECTIVE:

Malignant biliary obstruction (MBO) is a rare disease with a poor prognosis. Recent studies have shown that endoscopic radiofrequency ablation (ERFA) may improve survival. We conducted a systematic review and meta-analysis of the efficacy of ERFA in combination with biliary stent placement for the treatment of MBO.

METHODS:

The study was registered in INPLASY (number 202340096). The PubMed, Cochrane Library, Web of Science, and Embase databases were searched from inception to April 2023. We selected studies comparing the efficacy of ERFA plus stent placement with stent placement alone. The primary outcomes were pooled hazard ratios (HRs) for overall survival and stent patency; the secondary outcomes were the odds ratios (ORs) for adverse events.

RESULTS:

Eleven studies (four randomized controlled trials and seven observational studies) were included in the meta-analysis. Pooled analysis showed a difference in survival time between the two groups (HR 0.65, 95% confidence interval [CI] 0.58-0.73, I2 = 40%). However, there were no differences in the duration of stent patency or the incidence of adverse events (HR 1.04, 95% CI 0.84-1.29, I2 = 46%; OR 1.41, 95% CI 1.02-1.96, I2 = 29%).

CONCLUSIONS:

ERFA has a significant survival benefit for MBO, but does not increase the risk of adverse events.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de los Conductos Biliares / Stents / Colestasis / Ablación por Radiofrecuencia Tipo de estudio: Systematic_reviews Límite: Humans Idioma: En Revista: J Int Med Res Año: 2023 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de los Conductos Biliares / Stents / Colestasis / Ablación por Radiofrecuencia Tipo de estudio: Systematic_reviews Límite: Humans Idioma: En Revista: J Int Med Res Año: 2023 Tipo del documento: Article Pais de publicación: Reino Unido